MedWatch

Neurosearch sacks CEO

René Schneider has been fired as CEO of the Danish company Neurosearch, which was recently charged with market manipulation. The decision comes in an effort to save money, the company explains.

Foto: Jyllands-Posten

Neurosearch has taken the radical step of firing its CEO, René Schneider, in a bid to save money, the company announces in a stock market release.

“The reason for the termination is that the board – as a natural part of the chosen strategy for liquidation of company activities – wants to reduce the company’s daily operating costs,” the company writes.

Chairman of the Board, Allan Andersen, however, has nothing but praise for the work of the departing CEO.

“René has provided an excellent, dedicated and competent effort since joining Neurosearch. Under his leadership, the company’s equity has been restored, and bank debts have been settled. During this period, the company also managed to sell Huntexil, as well as company property and lands. The company is now in a position where the Board assesses that there is no longer any need for a strong CEO. We are certain that René will be successful in his future activities,” he says in the release.

René Schneider, who will be relieved of his official duties as of November 30, 2013, says he understands the Board’s decision.

“I have worked hard to bring Neurosearch to a place where the company’s activities were sold and debts settled in a successful manner. We have reached that place now, so I have great sympathy for the Board’s decision, and naturally it doesn’t come as a great surprise to me. Although I have been in charge of the company through a turbulent period, I’m very satisfied with my time at Neurosearch. I have done all I could to hand over a company in great shape,” he says.

Neurosearch informs that no decision has yet been made as to who will succeed René Schneider as CEO.

- translated by Martin Havtorn Petersen

Want to receive the latest news from Medwatch straight in your e-mail inbox? Sign up for our free english newsletter below.

Mere fra MedWatch

Direktør forlader svenske Lif

Anders Blanck, der siden 2011 har været adm. direktør i svenske Lif, har oplyst til bestyrelsen, at han ønsker at forlade posten.

Boston Scientific opkøber privatejet selskab

Amerikanske Boston Scientific har set sig lun på virksomheden Obsidio, der har udviklet en særlig teknologi til at lukke for blodtilførslen, og overtager ejerskabet i en handel uden oplyst pris.

Konservative tavse om modstand mod statsstøtte til Bavarian Nordic

Det Konservative Folkeparti stemte som eneste parti i Folketinget imod statsstøtten på op mod 800 mio. kr. til Bavarian Nordics udvikling af en covid-19-vaccine, men partiet ønsker ikke at kommentere, hvorfor de tog afstand fra det statslige samarbejde med virksomheden.

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier